Project Grant R01DK144047
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $2.4M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- This federal Project Grant award of $208,428, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research), aims to enhance the safety and efficacy of stem cell-derived islet transplantation for treating type 1 diabetes. The key objectives are to improve the survival and engraftment of the transplanted cells, enable long-term insulin independence, and develop safety mechanisms to retrieve the graft...
- This $681,562 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate approaches for enhancing the metabolic maturity and functionality of human pluripotent stem cell-derived islet organoids, with the goal of improving their survival and efficacy for transplantation as a treatment for type 1 diabetes. The research will examine the use of pharmacological agents...
- This $3,140,632 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research program) aims to elucidate the mechanisms underlying human endocrine lineage commitment and harness this knowledge to improve strategies for beta cell replacement in diabetes treatment. The 4-year project, awarded to the Regents of the University of California, San Francisco, seeks to enhance the...
- The federal Project Grant award of $287,250 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award was granted to Persista Bio Inc. to develop the manufacturing process for the cell capsule of the company's O2Line implant system, an advanced oxygenated cell encapsulation system targeting the treatment of type 1 diabetes (T1D). The key products to be...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $1,093,967 Project Grant to Persista Bio Inc. in Ithaca, NY. The grant supports the advanced preclinical development of the O2Line system, an oxygenated cell encapsulation device for type 1 diabetes cell replacement therapy. The goal is to develop a safe, anti-fibrotic, and high-capacity cell delivery system that...
- The federal Project Grant award R43DK137616 for $275,766.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds Biosurfaces Inc., a for-profit medical device company, to develop and evaluate an implantable, electrospun cell chamber device loaded with human pancreatic islets. The device aims to provide an immune-protected environment to support...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) provides $138,753 to The Washington University to support research on cytoskeletal regulation of gut tube organogenesis and subsequent maturation of stem cell-derived islets. The goal is to enable a cell-based therapy to become a viable and widely-used treatment option for type 1 diabetes, which results from the autoimmune destruction of insulin-producing beta cells. The research will...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $132,270 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Florida. The grant aims to develop a multi-functional 3D-printed biomaterial scaffold that improves the vascularization, engraftment, and immunoprotection of transplanted pancreatic islets for the treatment of type 1 diabetes. The project has two key objectives: 1) Identify...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $509,265.00 to Cornell University to develop a cell-retaining, subcutaneous device that allows blood vessel penetration and establishment of an immunotolerant environment for islet delivery for type 1 diabetes cell replacement therapy. The goal is to create a cell delivery...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $298,364 in funding to Immunoshield Therapeutics Inc. to investigate optimal islet density and dosage within macroencapsulation devices for clinical islet transplantation to treat type 1 diabetes. The research aims to address limitations in current macroencapsulation approaches, such as...